Diabetes and inflammatory diseases: An overview from the perspective of Ca2+/3'-5'-cyclic adenosine monophosphate signaling

doi:10.4239/wjd.v12.i6.767

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 12, Issue 6

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (7935)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Figures (1-2) series, Tables (1-2) series.

Item

Count

PDF

329

WORD

177

HTML

4510

Figures (1-2)

261

Tables (1-2)

306

Sum=5583

Featured Article

The chart showing Browse series, Download series.

Item

Count

Browse

538

Download

721

Sum=1259

Publishing Process of This Article

Item

Count

Browse

355

Download

738

Sum=1093

Jun 15, 2021 (publication date) through Nov 25, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Diabetes

ISSN

1948-9358

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Minireviews

World J Diabetes. Jun 15, 2021; 12(6): 767-779
Published online Jun 15, 2021. doi: 10.4239/wjd.v12.i6.767

Table 2 A list of several Ca²⁺ channel blockers and 3'-5'-cyclic adenosine monophosphate signaling-enhancer compounds

CCBs	cAMP signaling (enhancer compounds)
Verapamil	Rolipram
Nifedipine	3-isobutyl-1-methylxanthine (IBMX)
Diltiazem	Forskolin
Isradipine	Aminophylline
Amlodipine	Theophylline
Nicardipine	Paraxanthine

CCBs: Ca²⁺ channel blockers; cAMP: 3'-5'-cyclic adenosine monophosphate.

Citation: Bergantin LB. Diabetes and inflammatory diseases: An overview from the perspective of Ca²⁺/3'-5'-cyclic adenosine monophosphate signaling. World J Diabetes 2021; 12(6): 767-779
URL: https://www.wjgnet.com/1948-9358/full/v12/i6/767.htm
DOI: https://dx.doi.org/10.4239/wjd.v12.i6.767